SCHEMBL15930870

SCHEMBL15930870

COCC(=O)C1=C(CN2CC(C)CC(C)C2)NC(=O)NC1c1ccc(Cl)cc1

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.56
NPSR1 Q6W5P4 3/20 0.56
MEN1 O00255 2/20 0.56
KMT2A Q03164 2/20 0.56
RECQL P46063 1/20 0.56
CREBBP Q92793 1/20 0.56
GAA P10253 4/20 0.54
TP53 P04637 6/20 0.52
MAPT P10636 4/20 0.49
ALDH1A1 P00352 2/20 0.47
HTT P42858 1/20 0.47
THRB P10828 1/20 0.42
POLB P06746 1/20 0.41
KDM4E B2RXH2 1/20 0.41
MITF O75030 1/20 0.41
ALOX15 P16050 1/20 0.41
KLF5 Q13887 1/20 0.41
TDP1 Q9NUW8 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10113778 0.84 SMN1; SMN2 (0.78) SMN1; SMN2NPSR1MEN1KMT2ARECQL
SCHEMBL15930871 0.79 MAPT (0.75) SMN1; SMN2NPSR1MEN1KMT2ARECQL
SCHEMBL10113742 0.71 SMN1; SMN2 (1.00) SMN1; SMN2NPSR1MEN1KMT2ARECQL
SCHEMBL10113749 0.68 TP53 (0.88) SMN1; SMN2NPSR1MEN1KMT2ARECQL
SCHEMBL10113781 0.64 MAPT (1.00) SMN1; SMN2NPSR1MEN1KMT2ARECQL
SCHEMBL5340705 0.61 HSD17B10 (0.75) SMN1; SMN2KMT2AGAATP53ALDH1A1
SCHEMBL28562036 0.61 USP2 (0.75) SMN1; SMN2GAATP53ALDH1A1HTT
SCHEMBL3434652 0.59 MEN1 (0.64) SMN1; SMN2NPSR1MEN1KMT2ARECQL
SCHEMBL6346169 0.59 HTT (0.54) SMN1; SMN2MEN1KMT2AGAATP53
SCHEMBL4503574 0.59 ALDH1A1 (0.58) SMN1; SMN2MEN1KMT2AGAATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9815838-B2 Methods and compositions for treating pain HYDRA BIOSCIENCES, INC. (US) 2017-11-14 US disclosed
US-9815838-B2 Methods and compositions for treating pain HYDRA BIOSCIENCES, INC. (US) 2017-11-14 US disclosed
US-20140221401-A1 METHODS AND COMPOSITIONS FOR TREATING PAIN HYDRA BIOSCIENCES, INC. (US) 2014-08-07 US disclosed
US-20140221401-A1 METHODS AND COMPOSITIONS FOR TREATING PAIN HYDRA BIOSCIENCES, INC. (US) 2014-08-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140221401-A1 METHODS AND COMPOSITIONS FOR TREATING PAIN ACHE, COL2A1, MMP8 SMN1; SMN2 365/4885NPSR1 401/4885MEN1 4652/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.